Free Resource for Biopharma Deal Teams

Your Data Room Is Part of How Counterparties Evaluate You

Buyers, investors, and partners form an impression of your organization before they read a single number. This one-page reference covers what a deal-ready data room looks like for out-licensing, pre-IPO, and M&A, and what separates the rooms that accelerate deals from the ones that slow them down.

What the Datasheet Covers

A generic data room holds files. A deal-ready data room supports the process: staged IP access, controlled disclosure, version discipline, engagement visibility, and a clean audit trail. This one-page reference covers how ShareVault is built for each of the three major biopharma transaction types.

How to structure staged IP access for out-licensing and CDA-driven disclosure across multiple counterparties
What institutional investors expect from a pre-IPO data room and how engagement analytics inform your follow-up strategy
How to run a full M&A diligence process with separate permission tiers for acquirers, advisors, legal teams, and internal stakeholders
Why your data room audit trail matters for regulatory and legal defensibility
What deal teams at leading biopharma organizations say about using ShareVault in active transactions

The Room Signals More Than the Files

In biopharma transactions, the quality of your data room communicates something about the quality of your organization. A room that is disorganized, poorly permissioned, or difficult to navigate slows counterparty review, generates more questions, and introduces friction at exactly the point in the process where momentum matters most.

This datasheet is a one-page reference for deal teams who already understand VDRs and want to understand what a purpose-built biopharma data room looks like in practice. It is not an introduction to the category. It is a checklist for evaluating whether your current setup is actually built for the process you are running.

Pull Quote

“The platform’s intuitive design and robust activity monitoring, down to individual page views, enable meaningful follow-up and better-informed fundraising and partnering conversations.”

Jonas Ekblom,
CEO, Promore Pharma